aratinga.bio is a preclinical stage company founded in March 2017 developing novel immunotherapies to treat cancer. The company is developing its proprietary CAR T-cell platform to be effective against hematological cancers and solid tumors as well, regardless of the type of treatments patients have experienced before.
No funding announced yet
💡 You’re a corporate or investor and looking for startups that are innovating in the same market as aratinga.bio? We’re happy to assist you with our Startup Sourcing service.